Law360, New York (July 23, 2009, 4:22 PM ET) -- In an effort to secure a top position in the biologics industry, Bristol-Myers Squibb Co. has agreed to buy Medarex Inc., which develops human antibody-based therapeutics to treat life-threatening diseases, in a $2.1 billion deal that gives the drug giant full ownership rights to a promising treatment for melanoma.
The boards of directors at both drugmakers have unanimously approved a merger agreement providing for the acquisition of Medarex by Bristol-Myers for $16 per share in cash, Bristol-Myers announced Wednesday.
The total purchase price is $2.4 billion,...
Bristol-Myers To Purchase Medarex For $2.1B
To view the full article, take a free trial now.
